Korean J Urol.  2014 Mar;55(3):207-212. 10.4111/kju.2014.55.3.207.

Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Male Genital Warts

• Park SJ
• Seo J
• Ha SH
• Jung GW

• KMID: 1988426
• DOI: http://doi.org/10.4111/kju.2014.55.3.207

Abstract

PURPOSE
To evaluate the prevalence and type distribution of high-risk human papillomavirus (HPV) infection in genital warts of Korean men, and for the first time, to describe the risk factors associated with high-risk HPV infection in male genital warts.
MATERIALS AND METHODS
In a single private clinic, 150 consecutive male patients with histopathologic-confirmed genital warts who underwent HPV genotyping by use of polymerase chain reaction (PCR) were included in this study. We detected HPV DNA in male genital warts and evaluated HPV type distribution, especially high-risk HPV types, by use of PCR. The associations between HPV prevalence and various characteristics, such as age, circumcision status, type of genital warts diagnosis (new vs. recurrent), number of lesions, site of lesions, and gross morphology, were assessed by use of unconditional multiple logistic regression.
RESULTS
High-risk HPV types were detected in 31 cases (23.5%), and of these, 27 cases (20.5%) contained both high-risk and low-risk HPV types. The most frequently detected high-risk HPV types were HPV16 (6.8%), HPV33 (4.5%), HPV18 (2.3%), and HPV68 (2.3%). In particular, the prevalence of infection with HPV16 and/or HPV18 was 8.3% (11 of 132). In the multivariate analysis, lesions located at sites including the base of the penis or the pubic area, papular or mixed genital warts, and lack of circumcision significantly increased the association with high-risk HPV infection in male genital warts.
CONCLUSIONS
The prevalence of high-risk HPV infection was substantial in male genital warts. The site and morphology of lesions and circumcision status were significantly associated with the prevalence of high-risk HPV infection.

Keyword

Condylomata acuminate; Human papillomavirus 16; Polymerase chain reaction

MeSH Terms

Circumcision, Male
Condylomata Acuminata*
Diagnosis
DNA
Female
Human papillomavirus 16
Humans*
Logistic Models
Male*
Multivariate Analysis
Papillomavirus Infections*
Penis
Polymerase Chain Reaction
Prevalence*
Risk Factors
DNA

Reference

1. von Krogh G, Lacey CJ, Gross G, Barrasso R, Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect. 2000; 76:162–168.

2. Palefsky JM. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health. 2010; 46:4 Suppl. S12–S19.

3. Dempsey AF, Koutsky LA. National burden of genital warts: a first step in defining the problem. Sex Transm Dis. 2008; 35:361–362.

4. Harper DM. Why am I scared of HPV? CA Cancer J Clin. 2004; 54:245–247.

5. Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971; 47:1–13.

6. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001; 137:337–341.

7. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006; 61:6 Suppl 1. S3–S14.

8. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003; 36:1397–1403.

9. Jeynes C, Chung MC, Challenor R. 'Shame on you'--the psychosocial impact of genital warts. Int J STD AIDS. 2009; 20:557–560.

10. Burchell AN, Coutlee F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis. 2011; 204:1723–1729.

11. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008; 14:888–894.

12. Aubin F, Pretet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis. 2008; 47:610–615.

13. Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, et al. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol. 2009; 44:111–114.

14. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009; 199:805–814.

15. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis. 2011; 204:1886–1892.

16. Löwhagen GB, Bolmstedt A, Ryd W, Voog E. The prevalence of "high-risk" HPV types in penile condyloma-like lesions: correlation between HPV type and morphology. Genitourin Med. 1993; 69:87–90.

17. Lee GH. Use of consensus primer Set, GP5+ and GP6+, to detect human papillomavirus within genital lesions. Korean J Urol. 2003; 44:606–610.

18. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000; 38:357–361.

19. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10:321–322.

20. Lajous M, Mueller N, Cruz-Valdez A, Aguilar LV, Franceschi S, Hernandez-Avila M, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev. 2005; 14:1710–1716.

21. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003; 88:63–73.

22. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis. 2012; 205:1544–1553.

23. Campion MJ, Singer A, Clarkson PK, McCance DJ. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminata. Lancet. 1985; 1:943–946.

24. Kjaer SK, de Villiers EM, Dahl C, Engholm G, Bock JE, Vestergaard BF, et al. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the "male factor" in women with one lifetime sexual partner. Int J Cancer. 1991; 48:39–44.

25. Giuliano AR, Lazcano E, Villa LL, Flores R, Salmeron J, Lee JH, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer. 2009; 124:1251–1257.

26. Nielson CM, Schiaffino MK, Dunne EF, Salemi JL, Giuliano AR. Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. J Infect Dis. 2009; 199:7–13.

27. Muller EE, Chirwa TF, Lewis DA. Human papillomavirus (HPV) infection in heterosexual South African men attending sexual health services: associations between HPV and HIV serostatus. Sex Transm Infect. 2010; 86:175–180.

28. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009; 199:14–19.

29. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009; 360:1298–1309.

30. Wawer MJ, Tobian AA, Kigozi G, Kong X, Gravitt PE, Serwadda D, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet. 2011; 377:209–218.